David R. Bauer

Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…

Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.1 billion aggregate principal amount of senior notes, consisting…

Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and future success-based milestone payments. The transaction is…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an SEC-registered offering of common stock by iRhythm Technologies…

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Five Prime Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million. Five…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $125 million public offering of common stock by Personalis, Inc. The common stock…

Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…

Davis Polk advised the representatives of the underwriters in connection with an approximately $963.5 million public offering of ordinary shares of Horizon Therapeutics Public Limited…

Davis Polk advised Acutus Medical, Inc. on its SEC-registered initial public offering of 10,147,058 shares of common stock for an aggregate price to the public of approximately $170 million…